Benjamin Van Tassell
Virginia Commonwealth University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Benjamin Van Tassell as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:37 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05177822 · Interleukin-1 Blockade in Acute Myocardial Infarction to Prevent Heart FailureVirginia Commonwealth University · active not recruiting · Heart Failure · principal investigator
- Ph2NCT03797001 · Interleukin-1 Blockade In Recently Decompensated Heart Failure - 2Virginia Commonwealth University · completed · Heart Failure, Systolic, Inflammation · principal investigator
- N/ANCT03323840 · Pilot for a Community Pharmacy Service Model: Impact of a Pharmacist Monitored Patient Blood Pressure ReadingsVirginia Commonwealth University · completed · Hypertension · principal investigator
- Ph2NCT02173548 · Interleukin-1 Blockade in HF With Preserved EFVirginia Commonwealth University · completed · Heart Failure With Normal Ejection Fraction · principal investigator
- Ph1/Ph2NCT01936896 · Alpha-1 Anti-Trypsin (AAT) Treatment in Acute Myocardial InfarctionVirginia Commonwealth University · completed · Acute Myocardial Infarction · principal investigator
- Ph1/Ph2NCT01479010 · Pilot Study of the Safety and Efficacy of Anakinra (Recombinant Human Interleukin-1 Receptor Antagonist) in Pulmonary HypertensionVirginia Commonwealth University · terminated · Pulmonary Hypertension · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:37 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Prevention of heart failure with IL-1 blockade: a mechanistic studyR01AG076360 · NIA · VIRGINIA COMMONWEALTH UNIVERSITY · fiscal years 2022 to 2025 · $608,382 awarded in 2025Grant number is on one of their registry trials
- The Effects of Interleukin-1 Blockade On Exercise Capacity In Patients With Recently Decompensated Systolic Heart FailureR33HL139943 · NHLBI · VIRGINIA COMMONWEALTH UNIVERSITY · fiscal years 2019 to 2022 · $573,435 awarded in 2022Same name and institution; not confirmed by an ID
- The Effects of Interleukin-1 Blockade On Exercise Capacity In Patients With Recently Decompensated Systolic Heart FailureR61HL139943 · NHLBI · VIRGINIA COMMONWEALTH UNIVERSITY · fiscal years 2018 · $532,674 awarded in 2018Same name and institution; not confirmed by an ID
- Interleukin-1 blockade in acute myocardial infarctionR34HL121402 · NHLBI · VIRGINIA COMMONWEALTH UNIVERSITY · fiscal years 2014 to 2016 · $221,811 awarded in 2016Same name and institution; not confirmed by an ID
- Interleukin-1 blockade in heart failure with preserved ejection fractionR34HL118348 · NHLBI · VIRGINIA COMMONWEALTH UNIVERSITY · fiscal years 2014 to 2015 · $337,978 awarded in 2015Grant number is on one of their registry trials
- Interleukin-1 blockade in recently decompensated heart failureR34HL117026 · NHLBI · VIRGINIA COMMONWEALTH UNIVERSITY · fiscal years 2013 to 2014 · $340,316 awarded in 2014Same name and institution; not confirmed by an ID
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.